{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:41:10Z","timestamp":1740163270058,"version":"3.37.3"},"reference-count":24,"publisher":"BMJ","issue":"e3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2023,2,28]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Dexamethasone sparing strategies have shown success. The feasibility of a dexamethasone-free antiemetic strategy remains undetermined. A prospective, single-arm, pilot study was planned to determine the efficacy of an olanzapine-based, dexamethasone-free, three-drug antiemetic regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Chemotherapy na\u00efve, adult patients (\u226518 years) who received ondansetron, aprepitant and olanzapine during the first cycle of highly emetogenic chemotherapy were enrolled. The primary endpoint was the rate of complete response (CR: no vomiting and no use of rescue medications) during the overall period (0\u2013120\u2009hours).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of the total of 101 patients enrolled, most were women (82%) and received anthracycline cyclophosphamide (73%) combination therapy. The rate of CR for the overall period was 65% (95% CI 55.2% to 74.5%). The rate of CR for the acute and delayed period was 79% (95% CI 70% to 86.7%) and 76% (95% CI 66.7% to 84.1%). The rate of nausea control rates for the acute, delayed and overall periods were 34%, 29% and 24%, respectively. The grade I, II and III sedation rates over the 5\u2009days were 8%, 5% and 1%, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The dexamethasone-free antiemetic strategy showed modest efficacy with low incidence of clinically significant somnolence. There is a need to prospectively investigate the role of dexamethasone in the era of newer potent antiemetics in a randomised fashion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>CTRI\/2021\/07\/034813.<\/jats:p><\/jats:sec>","DOI":"10.1136\/spcare-2022-003864","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T17:20:49Z","timestamp":1678987249000},"page":"e867-e871","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Dexamethasone-free antiemetic strategy for highly emetogenic chemotherapy: safety and efficacy-pilot study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-5449","authenticated-orcid":false,"given":"Vinod","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Baa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Kirar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9367-4407","authenticated-orcid":false,"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhat Singh","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Batra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepam","family":"Pushpam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babita","family":"Kataria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hari","family":"Sagiraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwajeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"2024121022580595000_13.e3.e867.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"2024121022580595000_13.e3.e867.2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","article-title":"2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt","year":"2017","journal-title":"Support Care Cancer"},{"key":"2024121022580595000_13.e3.e867.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515442"},{"key":"2024121022580595000_13.e3.e867.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"2024121022580595000_13.e3.e867.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"key":"2024121022580595000_13.e3.e867.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"2024121022580595000_13.e3.e867.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.4375"},{"key":"2024121022580595000_13.e3.e867.8","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1200\/JCO.2000.18.19.3409","article-title":"Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence","volume":"18","author":"Ioannidis","year":"2000","journal-title":"J Clin Oncol"},{"key":"2024121022580595000_13.e3.e867.9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024121022580595000_13.e3.e867.10","doi-asserted-by":"crossref","first-page":"103143","DOI":"10.1016\/j.critrevonc.2020.103143","article-title":"Efficacy of intravenous NEPA, a fixed nk1\/5-ht3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC) -based chemotherapy: a review of phase 3 studies","volume":"157","author":"Aapro","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024121022580595000_13.e3.e867.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp584"},{"key":"2024121022580595000_13.e3.e867.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0941-7"},{"key":"2024121022580595000_13.e3.e867.13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu101"},{"key":"2024121022580595000_13.e3.e867.14","doi-asserted-by":"crossref","first-page":"103012","DOI":"10.1016\/j.critrevonc.2020.103012","article-title":"Duration of dexamethasone administration for the prevention of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis","volume":"152","author":"Raghunath","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024121022580595000_13.e3.e867.15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.18104","article-title":"Bone health and glucocorticoid-containing lymphoma therapy-a review of risk factors and preventative measures","volume":"198","author":"Eyre","year":"2022","journal-title":"Br J Haematol"},{"key":"2024121022580595000_13.e3.e867.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603048"},{"key":"2024121022580595000_13.e3.e867.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.2145","article-title":"LBA64 olanzapine, an alternative to dexamethasone for preventing nausea and vomiting induced by cisplatin-based doublet highly emetogenic chemotherapy: a non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial","volume":"32","author":"Liu","year":"2021","journal-title":"Annals of Oncology"},{"key":"2024121022580595000_13.e3.e867.18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0310057X1504300203","article-title":"Dexamethasone-an effective antiemetic, but is it safe?","volume":"43","author":"Short","year":"2015","journal-title":"Anaesth Intensive Care"},{"key":"2024121022580595000_13.e3.e867.19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4143\/crt.2015.464","article-title":"A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients","volume":"48","author":"Jeong","year":"2016","journal-title":"Cancer Res Treat"},{"key":"2024121022580595000_13.e3.e867.20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00277-022-04832-9","article-title":"Clinical interaction between dexamethasone and aprepitant in chemotherapy for lymphoma","volume":"101","author":"Hatano","year":"2022","journal-title":"Ann Hematol"},{"key":"2024121022580595000_13.e3.e867.21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1689-6"},{"key":"2024121022580595000_13.e3.e867.22","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41388-021-01944-w","article-title":"Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"key":"2024121022580595000_13.e3.e867.23","doi-asserted-by":"crossref","first-page":"i68","DOI":"10.1093\/bja\/aet577","article-title":"Association between preoperative glucocorticoids and long-term survival and cancer recurrence after colectomy: follow-up analysis of a previous randomized controlled trial","volume":"113 Suppl 1","author":"Singh","year":"2014","journal-title":"Br J Anaesth"},{"key":"2024121022580595000_13.e3.e867.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2291"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2022-003864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T07:15:59Z","timestamp":1733901359000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2022-003864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":24,"journal-issue":{"issue":"e3","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/spcare-2022-003864"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2022-003864","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"type":"print","value":"2045-435X"},{"type":"electronic","value":"2045-4368"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}